Nerandomilast (BI 1015550) is an orally active inhibitor of PDE4B with an IC50 value of 7.2 nM. Nerandomilast has good safety and potential applications in inflammation, allergic diseases, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD).

Zagociguat is the stimulator of soluble guanylate cyclase. Zagociguat increases nitric oxide (NO) signaling leading to an increase in cyclic guanosine monophosphate production. Zagociguat has the potential for the research of noncentral nervous system (CNS) disorders.

Isradipine(Dynacirc) is a calcium channel blocker with an IC50 of 34±8 μM.

MAGL-IN-1 is a potent, selective, reversible and competitive inhibitor of MAGL, with an IC50 of 80 nM. MAGL-IN-1 exhibits anti-proliferative effects against human breast, colorectal, and ovarian cancer cells. MAGL-IN-1 blocks MAGL in cell-based as well as in vivo assays.

D-Glucose-13C6 is a stable isotope-labeled counterpart of D-glucose (HY-B0389). D-Glucose-13C6 can be used as a metabolic tracer to trace glucose-related synthetic catabolism or as synthesis ingredient, minimal media reagent, and internal standard.

A potent HCV NS5B RNA polymerase inhibitor.

MW01 is a specific inhibitor for DNA damage-induced NF-κB activity, inhibits CLK2 and CLK4 with IC50 of 360 and 14.1 nM, does not inhibit CLK3.

MTB-9655 is a novel, potent and selective Acetyl-Coenzyme A Synthetase 2 (ACSS2) inhibitor, which is currently in Phase I clinical investigation on patients with tumors with high levels of ACSS2.

(S)-CKi-1 is a selective, covalent inhibitor of creatine kinases (CKs), inhibits recombinant creatine kinase B (CKB) phosphotransfer activity with IC50 of 0.6 uM, depletes creatine phosphagen energetics in cells.

DS-2330 is a phosphorous lowering agent for treating hyperphosphatemia in chronic kidney disease..

Balsalazide Disodium is the disodium salt form of balsalazide, an aminosalicylate and oral prodrug that is enzymatically cleaved in the colon to produce the anti-inflammatory agent mesalazine. Mesalazine acts locally on the mucosa of the colon where it diminishes inflammation by blocking the production of arachidonic acid metabolites and other inflammatory agents. Balsalazide disodium is used to treat chronic inflammatory bowel disease.

MitoPQ, also known as MitoParaquat, is a redox cycler. MitoParaquat (MitoPQ) that comprises a triphenylphosphonium lipophilic cation conjugated to the redox cycler paraquat. MitoPQ accumulates selectively in the mitochondrial matrix driven by the membrane potential. Within the matrix, MitoPQ produces superoxide by redox cycling at the flavin site of complex I, selectively increasing superoxide production within mitochondria. MitoPQ increased mitochondrial superoxide in isolated mitochondria and cells in culture ~a thousand-fold more effectively than untargeted paraquat. MitoPQ was also more toxic than paraquat in the isolated perfused heart and in Drosophila in vivo. MitoPQ enables the selective generation of superoxide within mitochondria and is a useful tool to investigate the many roles of mitochondrial superoxide in pathology and redox signaling in cells and in vivo.

Gliocidin is a prodrug that is anabolized into its tumoricidal metabolite, gliocidin–adenine dinucleotide (GAD). Gliocidin kills glioblastoma cells while sparing non-tumour replicative cells. Gliocidin activity targets a de novo purine synthesis vulnerability in glioblastoma through indirect inhibition of inosine monophosphate dehydrogenase 2 (IMPDH2). Gliocidin penetrates the blood–brain barrier and extends the survival of mice with orthotopic glioblastoma.

Rebecsinib (17S-FD-895) is a selective small-molecule inhibitor of splicing-mediated ADAR1 activation, prevents leukemia stem cell generation.

BTRX-335140 (CYM-53093, BTRX335140, CYM53093) is a potent, selective, orally active κ opioid receptor (KOR) antagonist with IC50 of 0.8 nM.

DDD 85646 is a potent, specific, dual N-Myristoyltransferase NMT1/NMT2 inhibitor with IC50 of 17 nM/22 nM respectively.

Compound C108 is a G3BP2 inhibitor. Compound C108 also targeted stress granule-associated proteins and Gtpase-activating protein (SH3 domain) binding protein 2. Compound C108 potently inhibits esophageal squamous cell carcinoma (ESCC) cell metastasis.

Sarolaner is a novel, orally administered, broad-spectrum, isoxazoline ectoparasiticide for dogs

Moxifloxacin(Avelox, Avalox) is a fourth generation synthetic fluoroquinolone antibacterial agent.

Azathioprine (Azasan, Imuran) is the analytical standard of Azathioprine. This product is intended for research and analytical applications. Azathioprine (BW 57-322) is an orally active immunosuppressive agent. Azathioprine can be converted in vivo to the active metabolite 6-mercaptopurine (6-MP). Azathioprine has myelosuppressive effects and induces apoptosis.

Cytosine β-D-arabinofuranoside hydrochloride is an anti-leukemic agent which binds to topoisomerase I resulting in DNA fragmentation and inhibition of replication. In addition this compound does not have any effects on RNA synthesis. Cytosine β-D-arabinof

Zinc Pyrithione is a dimer of two pyrithione molecules bound by zinc. It is commonly found as an ingredient of commercial anti-dandruff shampoos. This products acts as an antifungal and antibacterial.

Amprenavir (Agenerase) is a HIV protease inhibitor(Ki=0.6 nM) used to treat HIV infection.

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q).

ACR-2316 is a potentially first-in-class, potent, selective WEE1/PKMYT1 inhibitor with IC50 of 2 nM/44 nM. ACR-2316 demonstrates greater potency in all cell lines tested compared to adavosertib and lunresertib.

Compound 3 (AKT1/E17K inhibitor) is an allosteric, lysine-targeted salicylaldehyde, AKT1 (E17K) inhibitors with IC50 of 0.6 nM and shows 28-fold and 103-fold selectivity over AKT1 (WT) and AKT2 (WT), respectively.

MS105 is a potent PTK6 PROTAC degrader. MS105 effectively reduces PTK6 protein levels, induces apoptosis, and inhibits growth and migration of breast cancer cell lines of diverse subtypes.

Cis-AGB1 is a negative control for AGB1 . Exhibits no significant VHL binding affinity.

Selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6